John M. Climaco - 17 Nov 2025 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CNSP
Reported as of: 17 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Nov 2025, 17:00:07 UTC
Prior SEC filing: 14 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Christopher Downs, Attorney-in-Fact

Key filing fact

John M. Climaco filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 19 Nov 2025.

Key facts

This page summarizes John M. Climaco's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Nov 2025, 17:00.

Change

Previous filing in this sequence was filed on 14 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001546797 Primary reporting owner

Climaco John M

Relationship: Chief Executive Officer, Director
Address: C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON
Signature: /s/ Christopher Downs, Attorney-in-Fact
Signature date: 19 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNSP transaction Derivative

Option to purchase common stock

Award

Transaction value: $0
Shares: +9,761
Change %
Price: $0.000000
Shares after: 9,761
Date: 17 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,761
Exercise price: $30.00
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.

Footnote F2

The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.

Footnote F3

Issued in connection with the reporting person's employment with the Company.